Comparison 4. Combination therapies: Drug A vs Drug B.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Death due to HAT	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
1.1 Eflornithine‐nifurtimox vs melarsoprol‐eflornithine	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 Eflornithine‐nifurtimox vs melarsoprol‐nifurtimox	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.3 Melarsoprol‐eflornithine vs melarsoprol‐nifurtimox	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Death during treatment	3		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
2.1 Melarsoprol vs melarsoprol + prednisolone	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.2 Melarsoprol‐nifurtimox (10 days) vs melarsoprol (standard 3.6 mg)	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.3 Melarsoprol‐nifurtimox vs melarsoprol (incremental 10 days)	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.4 Melarsoprol‐nifurtimox vs nifurtimox (14 days)	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.5 Eflornithine (14 days) vs eflornithine+nifurtimox	0		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.6 Eflornithine‐nifurtimox vs melarsoprol‐eflornithine	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.7 Eflornithine‐nifurtimox vs melarsoprol‐nifurtimox	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.8 Melarsoprol‐eflornithine vs melarsoprol‐nifurtimox	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Overall mortality	2		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.1 Melarsoprol‐nifurtimox (10 days) vs melarsoprol (standard 3.6 mg)	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.2 Melarsoprol‐nifurtimox vs melarsoprol (incremental 10 days)	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.3 Melarsoprol‐nifurtimox vs nifurtimox (14 days)	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.4 Eflornithine (14 days) vs eflornithine+nifurtimox	0		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.5 Eflornithine‐nifurtimox vs melarsoprol‐eflornithine	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.6 Eflornithine‐nifurtimox vs melarsoprol‐nifurtimox	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.7 Melarsoprol‐eflornithine vs melarsoprol‐nifurtimox	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Relapse during follow up	3		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1 Melarsoprol vs melarsoprol + prednisolone	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.2 Melarsoprol‐nifurtimox (10 days) vs melarsoprol (standard 3.6 mg)	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.3 Melarsoprol‐nifurtimox vs melarsoprol (incremental 10 days)	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.4 Melarsoprol‐nifurtimox vs nifurtimox (14 days)	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.5 Eflornithine (14 days) vs eflornithine+nifurtimox	0		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.6 Eflornithine‐nifurtimox vs melarsoprol‐eflornithine	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.7 Eflornithine‐nifurtimox vs melarsoprol‐nifurtimox	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.8 Melarsoprol‐eflornithine vs melarsoprol‐nifurtimox	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]